Navigation Links
Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
Date:8/6/2014

m those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 Regulus Therapeutics Inc.Selected Financial InformationCondensed Statement of Operations(In thousands, except share and per share data)Three months ended
June 30,Six months ended
June 30,2014

2013

2014

2013(Unaudited)Revenues:Revenue under strategic alliances and collaboration

$ 736

$ 4,759

$ 2,367

$ 7,997Operating expenses:Research and development

10,795

7,722

20,399

14,604General and administrative

2,954

1,723

5,686

3,628Total operating expenses
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
2. Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
3. Regulus Announces Addition to NASDAQ Biotechnology Index
4. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
5. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
6. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
7. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
8. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
9. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
10. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
11. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... BARCELONA, Spain , April 24, 2015  Elekta ... popular Monaco® treatment planning system , enabling European ... that supports major treatment techniques including advanced 3D planning, ... single system. Monaco ... enhancements, as well improved workflow efficiency. Advancements in 3D ...
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
(Date:4/23/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $422.5 million, a 6 percent ... (a 13 percent increase on a constant currency basis).  ... percent compared to the quarter ended March 31, 2014.  ... an increase of 2 percent compared to the quarter ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13
... Landauer, Inc. (NYSE: LDR) announced today that ... of $0.55 per share for the second quarter of fiscal ... shareholders of record on March 9, 2012. ... technical and analytical services to determine occupational and environmental radiation ...
... 2012  In an effort to maximize business impact and ... research leaders must constantly evaluate the manner in which ... understand the optimal balance of external contract employees in ... quickly changing healthcare industry. To identify innovative ...
Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
(Date:4/26/2015)... Lauderdale, FL (PRWEB) April 26, 2015 ... 1,200 pieces of medical equipment from hospitals, surgery centers ... types of equipment will be sold including radiology, surgery, ... The live auction will take place Tuesday, April 28th ... Fort Lauderdale warehouse located at 5025 North Hiatus Rd., ...
(Date:4/26/2015)... In an article published last month ... head-neck biomechanics occurring during the use of handheld electronic devices ... determine that use of a tablet increases mechanical demand on ... - more than when the neck is in a neutral ... but pointing out the potential hazards of overuse of mobile ...
(Date:4/26/2015)... April 26, 2015 MidSouth Pain ... throughout the Southeast. MidSouth Pain Treatment Center is a ... Cordova, Southaven, Oxford and Jackson, two ambulatory surgery centers ... the Southaven and Cordova locations. , Dr. Michael ... went into medicine to help people, and when I ...
(Date:4/25/2015)... Avid Collector Andrew Hawley from Vintage Rock ... Coliseum concert posters. The concert was held on 12 ... American Tour. , According to Hawley, “The poster ... Maryland. This poster blank was used to advertise the ... uses garish lettering and colors on this boxing style ...
(Date:4/25/2015)... Jersey (PRWEB) April 25, 2015 In ... aged twelve and above needed treatment for an ... to the Substance Abuse and Mental Health Services Administration’s ... 2011). Beyond these alarming numbers are harrowing stories of ... substance abuse . David H. Kerr , ...
Breaking Medicine News(10 mins):Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3
... News) -- People affected by epilepsy are nearly eight ... schizophrenia, and those with schizophrenia are also six times ... not schizophrenic, a new study suggests. Researchers in ... may be due to genetic, environmental or neurobiological causes. ...
... the Mining Microbial Genomes for Novel Antibiotics research theme ... a recipient of the 2011 National Institutes of Health ... from some of the nation,s most promising new scientists. ... of five years, supports young investigators who have proposed ...
... Talking with doctors about cancer and cancer treatments can feel ... often need help to understand their treatment options, and the ... making life and death decisions that may affect their survival ... Cancer treatments and tests can be serious. Patients need to ...
... DURHAM, N.C. An analysis of more than 30,000 cancer ... complication than doctors may realize, causing additional hospitalizations and driving ... by a Duke Cancer Institute researcher. The study, which ... Cancer Congress in Stockholm, found that as many as one ...
... based method of family planning developed by researchers from ... so effectively meets the needs of users that they continue ... finds that women who follow the Standard Days Method, are ... effectively. Results of the large, multi-country study of 1659 women ...
... new type of nanoparticle developed in the laboratories at the ... delivery of chemotherapy to treat cancer. Wenbin Lin, PhD, ... their finding in the Sept. 14, 2011 issue of ... laboratory studies, Lin and colleagues developed and tested a new ...
Cached Medicine News:Health News:Researchers Find Link Between Epilepsy, Schizophrenia Risk 2Health News:10 ways to make better decisions about cancer care 2Health News:10 ways to make better decisions about cancer care 3Health News:Costly blood clots more common than expected among cancer patients 2Health News:Long-term effectiveness of new family planning method shown in study 2Health News:UNC scientist proves potential of new nanoparticle design for cancer therapy 2
Reliavac® 400cc kits with siliconized PVC drain, Y-connector tube...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used with T-tubes to collect drainage after cholecystectomy. Includes T-tube adapter and two adjustable latex rubber belts....
Used following hysterectomy procedure. Often attached to Bard bile bag....
Medicine Products: